Liprolog Junior Kwikpen (Insulin Lispro)

Liprolog Junior Kwikpen contains insulin lispro, a rapid‑acting insulin analog that works within the insulin‑dependent glucose regulation pathway. It is indicated for the following clinical situations:

• Type 1 diabetes mellitus: provides mealtime glucose control and reduces post‑prandial hyperglycaemia.
• Type 2 diabetes mellitus: used when oral agents are insufficient to achieve glycaemic targets.
• Intensive insulin therapy (basal‑bolus regimen): serves as the rapid‑acting component to complement basal insulin for tight glucose management.

• Insulin lispro binds to the insulin receptor on muscle and adipose cells, activating the receptor’s tyrosine kinase activity. This promotes translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake, while simultaneously inhibiting hepatic gluconeogenesis and glycogenolysis, leading to rapid reduction of circulating blood glucose levels.

Common Side Effects

• Hypoglycaemia: low blood glucose episodes, especially if meals are missed or dosing is excessive.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: modest increase associated with improved glucose utilisation.
• Lipodystrophy: localized changes in subcutaneous fat with repeated injections.

Serious or Rare Side Effects

• Severe hypoglycaemia: neurological impairment requiring immediate assistance.
• Anaphylactic reaction: systemic allergic response that may include rash, bronchospasm, or hypotension.
• Hypokalemia: low serum potassium levels, particularly with high insulin doses.
• Diabetic ketoacidosis: possible if insulin therapy is abruptly discontinued.

When using Liprolog Junior Kwikpen, consider the following precautions:

• Dose adjustment: tailor insulin dose to carbohydrate intake, physical activity, and glucose monitoring results.
• Hypoglycaemia risk: educate patients on recognising and treating low blood glucose promptly.
• Renal impairment: monitor renal function and adjust dose as needed because insulin clearance may be reduced.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the pen.

Insulin lispro may interact with several medicines that affect glucose levels or insulin action.

Major Interactions (Avoid)

• Beta‑blockers: can mask hypoglycaemia symptoms, making detection difficult.
• Alcohol: potentiates insulin’s glucose‑lowering effect and increases hypoglycaemia risk.
• Concurrent insulin products: additive glucose‑lowering effect may cause severe hypoglycaemia.

Moderate Interactions (Monitor Closely)

• Glucocorticoids: raise blood glucose and may require higher insulin doses.
• Thiazide diuretics: can increase blood glucose modestly.
• ACE inhibitors and ARBs: may enhance insulin sensitivity, necessitating dose review.